immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy.
immatics has a good track record of success: They are optimistic that they have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severe side effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors.
immatics is currently working on the development of new substances for a number of specific cancer types. Their most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. Final results for this trial are expected in 2015. A second product targeting colorectal cancer has just completed a large phase 1/2 clinical trial and a third cancer vaccine has entered several phase 1 clinical trials in brain cancer. They also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer which are being developed in collaboration with our partner Roche.
Funding Rounds (5) - $178.81MUpdate
Current Team (6)Update
|Sep 17, 2015||wellington-partners.com - http://www.wellington-partners.com/wp/downloads/wpn/2004/040211_wel.pdf|
|Jul 16, 2014||PE HUB - immatics raises final tranche of Series D fundraising|
|Jul 16, 2014||PRNewswire All - immatics Receives €22 Million Final Tranche of Series D Fundraising|
|Oct 15, 2013||FinSMEs - FinSMEs|
|Sep 21, 2010||immatics.com - immatics biotechnologies raises 70848000 in venture round|
|Mar 10, 2010||tornado-insider.com - immatics biotechnologies raises 51964000 in venture round|